Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 12	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 17	JUL 28	CA/CAplus patent coverage enhanced
NEWS 18	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20	JUL 28	STN Viewer performance improved
NEWS 21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 24	AUG 15	CAplus currency for Korean patents enhanced
NEWS 25	AUG 25	CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS 26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:42:36 ON 08 SEP 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:42:45 ON 08 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    7 SEP 2008  HIGHEST RN 1047406-12-1
DICTIONARY FILE UPDATES:   7 SEP 2008  HIGHEST RN 1047406-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10596745s8.str
```





```
chain nodes :
2  3  4  6  7  9  10  12  13  14  15  22
ring/chain nodes :
1
chain bonds :
1-10  2-3  2-22  3-13  4-13  4-14  6-7  6-14  7-9  9-15  10-22  12-15
exact/norm bonds :
1-10  4-13  4-14  6-7  6-14  7-9  9-15  10-22  12-15
exact bonds :
2-3  2-22  3-13


G1:C,O,N,Cy

G2:C,O,N,Cy

Match level :
1:CLASS  2:CLASS  3:CLASS  4:Atom  6:CLASS  7:CLASS  9:CLASS  10:Atom  12:Atom
13:CLASS  14:CLASS  15:CLASS  22:CLASS
Element Count :
Node 10: Limited
    C,C4
    N,N2




L1      STRUCTURE UPLOADED

=> s l1 sss sam
SAMPLE SEARCH INITIATED 11:44:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    15463 TO ITERATE

 12.9% PROCESSED     2000 ITERATIONS                                 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       301811 TO   316709
PROJECTED ANSWERS:              74 TO      544

L2            2 SEA SSS SAM L1

=> s c6n2/rf
L3       52023 C6N2/RF

=> s c4n2/rf
L4     2537685 C4N2/RF

=> s l1 sss sub=l3 sam
SAMPLE SUBSET SEARCH INITIATED 11:44:46 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -       19 TO ITERATE

100.0% PROCESSED       19 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):           ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):          119 TO      641
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):               0 TO        0

L5            0 SEA SUB=L3 SSS SAM L1

=> s l1 sss sub=l4 sam
SAMPLE SUBSET SEARCH INITIATED 11:44:59 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -     1287 TO ITERATE

100.0% PROCESSED     1287 ITERATIONS                             15 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):           ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):        23588 TO    27892
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):              68 TO      532

L6           15 SEA SUB=L4 SSS SAM L1

=> d scan

L6   15 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-[2-
     fluoro-5-(trifluoromethyl)phenyl]-
MF   C16 H9 F4 N7 O S
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 15 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-methyl-3-isoxazolyl)-
MF C17 H14 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 15 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-
MF C21 H23 N7 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss sub=l4 full
FULL SUBSET SEARCH INITIATED 11:46:00 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -    26775 TO ITERATE

100.0% PROCESSED    26775 ITERATIONS                              317 ANSWERS
SEARCH TIME: 00.00.01

L7          317 SEA SUB=L4 SSS FUL L1

=> s l1 sss full
FULL SEARCH INITIATED 11:46:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   309531 TO ITERATE

100.0% PROCESSED   309531 ITERATIONS                              317 ANSWERS
SEARCH TIME: 00.00.03

L8          317 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                  368.86     369.07

FILE 'CAPLUS' ENTERED AT 11:46:37 ON 08 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 8 Sep 2008  VOL 149 ISS 11
FILE LAST UPDATED: 7 Sep 2008  (20080907/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l8 and l7
             9 L8
             9 L7
L9           9 L8 AND L7

=> d ibib abs hitstr 9

L9   ANSWER 9 OF 9  CAPLUS  COPYRIGHT 2008 ACS on STN
```

ACCESSION NUMBER: 2005:158661 CAPLUS
DOCUMENT NUMBER: 142:240460
TITLE: Preparation of pyrimidine derivatives as ErbB kinase inhibitors
INVENTOR(S): Reno, Michael John; Stevens, Kirk Lawrence; Waterson, Alex Gregory; Zhang, Yuemei
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016914	A1	20050224	WO 2004-US26251	20040811
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1654251	A1	20060510	EP 2004-781004	20040811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007502298	T	20070208	JP 2006-523388	20040811
US 20060205740	A1	20060914	US 2006-568052	20060210
PRIORITY APPLN. INFO.:			US 2003-495180P	P 20030814
			WO 2004-US26251	W 20040811

OTHER SOURCE(S): CASREACT 142:240460; MARPAT 142:240460
GI



I



II

AB Title compds. I [wherein A = alkenylene, alkynylene; R = alkylene; R1 = -(Z)-(Z1)m-(Z2)n; Z = hetero/aryl, hetero/arylene; Z1 = CH2 where m = 0-1; Z2 = OH and derivs., halo, CN, CONH2 and derivs. or heterocyclyl, where n = 0-1, etc.; R2 = H, alkyl; R3 = -(Q)-(Q1)r-(Q2); Q = hetero/arylene; Q1 = O, where r = 0-1; Q2 = arylalkyl, hetero/aryl; and their salts, solvates, and physiol. functional derivs.] were prepared as ErbB kinase inhibitors for treating cancer. Thus, reacting 2-benzyl-N-(5-vinylpyrimidin-4-yl)-1H-benzimidazol-5-amine (preparation given) with Ph iodide gave pyrimidine II in 8%. I showed inhibitory activity vs. EGFR, ErbB-2, and ErbB-4 protein tyrosine kinases with a pIC50 ≥ 5.0. I are useful in the treatment of diseases associated with inappropriate ErbB family kinase activity.

IT 845657-86-5P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[[2-(4-morpholinyl)ethyl]amino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845657-90-1P, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-2-pyridinyl]ethynyl]-4-pyrimidinamine 845658-10-8P, 1-[[6-[[4-[3-Chloro-4-[(3-fluorobenzyl)oxy]anilino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-3-[2-(4-morpholinyl)ethyl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrimidines as ErB kinase inhibitors)

RN 845657-86-5 CAPLUS

CN 4-Morpholineethanamine, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]- (CA INDEX NAME)



RN 845657-90-1 CAPLUS
CN 4-Pyrimidinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-[6-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-2-pyridinyl]ethynyl]- (CA INDEX NAME)



RN 845658-10-8 CAPLUS
CN Urea, N-[[6-[2-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-pyrimidinyl]ethynyl]-2-pyridinyl]methyl]-N'-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 8

L9 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:588667 CAPLUS
DOCUMENT NUMBER: 143:115556
TITLE: Preparation of 4-aminopyrimidine derivatives as inhibitors of Tie2 receptor tyrosine kinases
INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur; McCoull, William
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060969	A1	20050707	WO 2004-GB5332	20041220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1737462	A1	20070103	EP 2004-806134		20041220
EP 1737462	B1	20080730			
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 1917880	A	20070221	CN 2004-80041936		20041220
JP 2007517006	T	20070628	JP 2006-546305		20041220
US 20080027076	A1	20080131	US 2006-596740		20060622
IN 2006MN00847	A	20070420	IN 2006-MN847		20060717
PRIORITY APPLN. INFO.:			GB 2003-30001	A	20031224
			GB 2004-16850	A	20040729
			WO 2004-GB5332	W	20041220

OTHER SOURCE(S): CASREACT 143:115556; MARPAT 143:115556

GI



I



II

AB Title compds. I [wherein R1, R2 = H, alkyl, alkanoyl; R3, R4 = H, alkyl, alkoxy; R5 = cyclopropyl, halo, cyano; m, n = 0-3; R6 = halo, oxo, cyano; etc., or salts thereof] were prepared as inhibitors of Tie2 receptor tyrosine kinases. Processes for the synthesis of I and some intermediates involved are claimed. For example, urea II was synthesized in 21% yield by condensation of the corresponding aniline with Ph thiadiazolylcarbamate in the presence of Et3N in THF under microwave irradiation This urea showed inhibition against Tie2 receptor tyrosine kinase in vitro and inhibition of autophosphorylation of Tie2 receptor tyrosine kinase with IC50 values of 0.879 μM and 5.557 μM, resp. Therefore, I and their pharmaceutical compns. have potential use in the production of an anti-angiogenic effect in a warm-blooded animal.

IT 857287-13-9P, Phenyl [3-[(4,6-diaminopyrimidin-5-

yl)ethynyl]phenyl]carbamate 857287-53-7P, N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[4-[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)

RN 857287-13-9 CAPLUS
CN Carbamic acid, [3-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 857287-53-7 CAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[4-[[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



IT 857287-02-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-phenylurea 857287-04-8P, 2-Phenyl-N-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]acetamide 857287-05-9P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3,4-dichlorophenyl)urea 857287-06-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-(trifluoromethyl)phenyl]urea 857287-07-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[3-(trifluoromethyl)phenyl]urea 857287-08-2P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]urea 857287-09-3P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea 857287-10-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methoxyphenyl)urea 857287-11-7P, Phenyl [4-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857287-14-0P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[4-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-15-1P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisothiazol-5-yl)urea 857287-16-2P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857287-17-3P, N-[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857287-18-4P, N-[3-[[[4-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide 857287-19-5P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisothiazol-5-yl)urea 857287-20-8P , N-[3-[[[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]amino]carbonyl]ami

no]phenyl]acetamide 857287-21-9P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857287-22-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5-yl)urea 857287-23-1P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-24-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[(4,6-diaminopyrimidin-5-yl)ethynyl]phenyl]urea 857287-25-3P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,3-dihydro-1,4-benzodioxin-6-yl)urea 857287-26-4P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-[2-(morpholin-4-yl)phenyl]urea 857287-27-5P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-methylpiperidin-4-yl)urea 857287-28-6P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-propylpiperidin-4-yl)urea 857287-29-7P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857287-30-0P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide 857287-31-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-[4-(trifluoromethyl)phenyl]acetamide 857287-32-2P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methoxyphenyl)acetamide 857287-35-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-(methylamino)pyrimidin-5-yl]ethynyl]phenyl]urea 857287-36-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(isopropylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-37-7P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-38-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(5-tert-butylisoxazol-3-yl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-39-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-40-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(2-hydroxyethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-41-3P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-42-4P, N-[3-[[4-[(4-Aminobutyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857287-43-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(pyrrolidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-44-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[(2,4-dimethoxybenzyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-45-7P, N-[3-[[4-[(2-Aminoethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857287-46-8P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(dimethylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-47-9P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[4-(dimethylamino)butyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-48-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[N-[2-(dimethylamino)ethyl]methylamino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-49-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[2-(piperidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-50-4P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-51-5P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-52-6P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[4-[[3-(4-methylpiperazin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857287-57-1P, N-[3-[(4,6-Diaminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2,3-dihydro-1H-inden-1-yl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of aminopyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)

RN 857287-02-6 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)



RN 857287-04-8 CAPLUS
CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-05-9 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,4-dichlorophenyl)- (CA INDEX NAME)



RN 857287-06-0 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 857287-07-1 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 857287-08-2 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 857287-09-3 CAPLUS
CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 857287-10-6 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methoxyphenyl)- (CA INDEX NAME)



RN 857287-11-7 CAPLUS
CN Carbamic acid, [4-[(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 857287-14-0 CAPLUS
CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 857287-15-1 CAPLUS
CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isothiazolyl)- (CA INDEX NAME)



RN 857287-16-2 CAPLUS
CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)



RN 857287-17-3 CAPLUS
CN Urea, N-[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 857287-18-4 CAPLUS
CN Acetamide, N-[3-[[[[4-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 857287-19-5 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isothiazolyl)- (CA INDEX NAME)



RN 857287-20-8 CAPLUS
CN Acetamide, N-[3-[[[[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



RN 857287-21-9 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 857287-22-0 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)



RN 857287-23-1 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 857287-24-2 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-25-3 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2,3-dihydro-1,4-benzodioxin-6-yl)- (CA INDEX NAME)



RN 857287-26-4 CAPLUS

CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 857287-27-5 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 857287-28-6 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-propyl-4-piperidinyl)- (CA INDEX NAME)



RN 857287-29-7 CAPLUS
CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy- (CA INDEX NAME)



RN 857287-30-0 CAPLUS
CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 857287-31-1 CAPLUS
CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 857287-32-2 CAPLUS
CN Benzeneacetamide, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-3-methoxy- (CA INDEX NAME)



RN 857287-35-5 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-(methylamino)-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-36-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-[(1-methylethyl)amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-37-7 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-38-8 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 857287-39-9 CAPLUS
CN Urea, N-[3-[2-[4-[[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-40-2 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[(2-

hydroxyethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-41-3 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-42-4 CAPLUS
CN Urea, N-[3-[2-[4-[(4-aminobutyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-43-5 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(1-pyrrolidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-44-6 CAPLUS
CN Urea, N-[3-[2-[4-[[(2,4-dimethoxyphenyl)methyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-45-7 CAPLUS
CN Urea, N-[3-[2-[4-[(2-aminoethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-46-8 CAPLUS
CN Urea, N-[3-[2-[4-[[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-47-9 CAPLUS
CN Urea, N-[3-[2-[4-[[4-(dimethylamino)butyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-48-0 CAPLUS
CN Urea, N-[3-[2-[4-[[2-(dimethylamino)ethyl]methylamino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)



RN 857287-49-1 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[2-(1-piperidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-50-4 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-51-5 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-52-6 CAPLUS
CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[4-[[3-(4-methyl-1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)



RN 857287-57-1 CAPLUS
CN Urea, N-[3-[2-(4,6-diamino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2,3-dihydro-1H-inden-1-yl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	13.78	382.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

STN INTERNATIONAL LOGOFF AT 11:49:57 ON 08 SEP 2008